Archives → 2023 → Vol. 63, № 3 → pp. 261–269
Article
Molgramostim Efficiency Trial in Acute Radiation Damage (Experimental Study)
A. Yu. Kondakov, I. S. Drachyov, D. V. Remizov, M. A. Karamullin, P. V. Tihomirov, E. B. Suprunova, E. A. Yakunchikova, O. A. Danilova
State Scientific Research Test Institute of Military Medicine, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia
Abstract
The purpose of the study was to study the specific activity of the drug molgramostim (Neostim®) under conditions of a single general γ-irradiation. Evaluation of the anti-radiation efficacy of the conducted studies, studying the 30-day survival rate and life expectancy of irradiated (at doses of 4, 5, 6, 7, 8 Gy) mice, as well as the dynamics of peripheral blood, extramedlar and bone marrow hematopoiesis. It has been established that 14-fold (with an interval of 12 hours) subcutaneous administration of the drug molgramostim at a dose of 5 μg/kg to mice after irradiation at an average lethal dose (6 Gy) has a pronounced anti-radiation effect. The value of the dose change factor when the drug is administered at the optimal dose is 1.16. The use of molgramostim increases the survival rate of mice by 30%, contributes to an earlier, compared with irradiated animals of the control group, restoration of the content of peripheral blood cells (by day 10, the number of leukocytes was 50% more, and the number of lymphocytes, erythrocytes and platelets – by 10% than in animals that did not receive the drug), as well as an increase in the number of endogenous CFU by 30% compared with the control and the number of bone marrow myelokaryocytes by an average of 1.2 times.
Keywords
Hematopoiesis, granulocyte-macrophage colony-stimulating factor, ionizing radiation, acute radiation injury, dose modificaton factor, endogenous colony formation
Current Issue
FAQs
Yes, authors are provided with pdf files. The files are sent to the authors' addresses specified in the file "Information about authors".
The average period from submission to first decision in last year was 30 days, and that from first decision to acceptance was 40 days. The rejection rate for submitted manuscripts in last year was 15%.